New England Journal of Medicine· 2012Q1

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu et al.

8,030citations
Q1SCImago
2012year

Short summary

An anti-PD-L1 antibody showed durable tumor regression and disease stabilization in patients with advanced cancers, with an objective response rate of 6-17% and 12-41% disease stabilization at 24 weeks.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine